A Phase 3 interventional study of Oxymetazoline HCL Cream 1.0% in Erythema and Rosacea, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Erythema with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Erythema · United States.
Among the 55 studies in Erythema with a site in United States, this one is the 2nd largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2014, is one of 5 in phase 3, and was the 15th registered.
131 studies on the registry are indexed under Erythema; 17 are open to participants now.
Browse Erythema studies →8 of the 55 studies in Erythema with a site in United States are open now. Recruiting first, the newest first:
Medicines Development for Global Health · Sites in United States, Benin, Côte D'Ivoire and 3 more countries
Ages 18+
Good Molecules, LLC · Sites in United States
Ages 18–75 · Healthy volunteers
University of Nevada, Las Vegas · Sites in United States
Ages 18+
Acorn Biolabs Inc. · Sites in United States, Canada
Ages 18+ · Healthy volunteers
Henry Ford Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Erythema studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 440 is above the median of 50 across 114 interventional studies indexed under Erythema.
Median enrollment 52 across the 52 interventional studies, 104 across the 3 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 7 studies filed under Erythema — fewer than ten, so there is no comparison to draw.
4 of the studies in Erythema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07172659Medicines Development for Global HealthEfficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction | 2027-01 |
| NCT06477172Acorn Biolabs Inc.Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures | 2027-02 |
| NCT07789639Good Molecules, LLCA Clinical Study to Evaluate the Efficacy and SPF of Two Test Materials According to an Adaptation of the Guidelines of the FDA Sunscreen Drug Products for Over-the-Counter Human Use | 2027-02-24 |
| NCT02876107M.D. Anderson Cancer CenterCarboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Erythema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Moderate to severe persistent facial erythema associated with rosacea.
Exclusion Criteria:
Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
Drug: Oxymetazoline HCL Cream 1.0%
Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
Also known as: AGN-199201
Percentage of Participants With Treatment-Related Adverse Events
An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A Treatment-Related Adverse Event is an Adverse Event determined by the investigator to be causally related to the study medication.
Time frame: 56 Weeks
Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales
The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 6-hour evaluation period (hours 3 and 6) post-dose.
Time frame: Baseline, Day 1 Hours 3 and 6, Week 4 Predose and Hours 3 and 6, Week 12 Predose, Week 26 Predose and Hours 3 and 6, Week 39 Predose, Week 52 Predose and Hours 3 and 6, Week 54 Predose
| Milestone | Oxymetazoline HCL Cream 1.0% |
|---|---|
| Started | 440 |
| Completed | 365 |
| Not completed | 75 |
| Withdrew: Adverse event | 14 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Lost to follow-up | 20 |
| Withdrew: Personal reasons | 35 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Other miscellaneous reasons | 1 |
An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A Treatment-Related Adverse Event is an Adverse Event determined by the investigator to be causally related to the study medication.
| percentage of participants | Oxymetazoline HCL Cream 1.0% |
|---|---|
| Percentage of Participants With Treatment-Related Adverse Events | 8.2 |
The investigator assessed the participant's overall severity of erythema in the treatment area by using the 5-point CEA scale with photonumeric guide where: 0=clear skin with no signs of erythema (best) to 4=severe erythema; fiery redness (worst). A decrease in the score indicates improvement. The participant assessed their overall severity of rosacea facial redness in the treatment area by using the 5-point SSA scale with photoguide where: 0=no signs of unwanted redness (best) to 4=severe redness (worst). A decrease in the score indicates improvement. The percentage of participants with at least a 2-grade decrease (improvement) on both CEA and SSA from Baseline was evaluated over the 6-hour evaluation period (hours 3 and 6) post-dose.
| percentage of participants | Oxymetazoline HCL Cream 1.0% |
|---|---|
| Day 1 (Hour 3) | 11.6 |
| Day 1 (Hour 6) | 17.8 |
| Week 4 (Predose) | 1.2 |
| Week 4 (Hour 3) | 19.5 |
| Week 4 (Hour 6) | 23.0 |
| Week 12 (Predose) | 6.1 |
| Week 26 (Predose) | 6.5 |
| Week 26 (Hour 3) | 34.7 |
| Week 26 (Hour 6) | 38.1 |
| Week 39 (Predose) | 9.5 |
| Week 52 (Predose) | 11.2 |
| Week 52 (Hour 3) | 36.7 |
| Week 52 (Hour 6) | 43.4 |
| Week 54 (Predose) | 12.1 |
Collected over Up to 56 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxymetazoline HCL Cream 1.0% | — | 15/440 (3.4%) | 0/440 (0%) |
| Event | Oxymetazoline HCL Cream 1.0% |
|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/440 |
| Angina pectorisCardiac disorders | 1/440 |
| Coronary artery diseaseCardiac disorders | 1/440 |
| Chest painGeneral disorders | 1/440 |
| CholecystitisHepatobiliary disorders | 1/440 |
| AppendicitisInfections and infestations | 1/440 |
| CellulitisInfections and infestations | 1/440 |
| Chronic sinusitisInfections and infestations | 1/440 |
| SepsisInfections and infestations | 1/440 |
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/440 |
| Age, Customized(participants) | Oxymetazoline HCL Cream 1.0% |
|---|---|
| 18 to 64 years | 370 |
| ≥ 65 years | 70 |
| Sex: Female, Male(Participants) | Oxymetazoline HCL Cream 1.0% |
|---|---|
| Female | 335 |
| Male | 105 |
The record gives a start of Apr 2014, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxymetazoline